Adma Biologics, Inc. (ADMA) SEC Filing 8-K Material Event for the period ending Thursday, April 30, 2020

Adma Biologics, Inc.

CIK: 1368514 Ticker: ADMA

View differences made from one to another to evaluate Adma Biologics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adma Biologics, Inc..


Assess how Adma Biologics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adma Biologics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: ADMA
CIK: 1368514
Form Type: 8-K Corporate News
Accession Number: 0001193805-20-000548
Submitted to the SEC: Fri May 01 2020 5:01:31 PM EST
Accepted by the SEC: Fri May 01 2020
Period: Thursday, April 30, 2020
Industry: Biological Products No Disgnostic Substances
  1. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: